Product lifecycle approach to cascade impaction measurements

AAPS PharmSciTech

Volumn 12, Issue 1, 2011, Pages 312-322

  Tougas, Terrence P ^a   Christopher, Dave ^b   Mitchell, Jolyon ^c   Lyapustina, Svetlana ^d   Van Oort, Michiel ^e   Bauer, Richard ^f   Glaab, Volker ^g  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b Merck   (United States)

^c TRUDELL MEDICAL INTERNATIONAL   (Canada)

^d Pharmaceutical Practice Group   (United States)

^e GLAXOSMITHKLINE   (United States)

^f MannKind Corporation   (United States)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

abbreviated impactor measurement (AIM); Andersen cascade impactor (ACI); inhaler; lifecycle; quality control (QC)

Indexed keywords

DRUG; ORALLY INHALED PRODUCT; UNCLASSIFIED DRUG;

ABBREVIATED IMPACTOR MEASUREMENT; AERODYNAMIC PARTICLE SIZE DISTRIBUTION DISTRIBUTION; ARTICLE; CASCADE IMPACTION MEASUREMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG DISTRIBUTION; EFFICIENT DATA ANALYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PARTICLE SIZE; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PRODUCT PARAMETERS; RESPIRATORY SYSTEM;

ADMINISTRATION, INHALATION; ADULT; EQUIPMENT DESIGN; HUMANS; MATERIALS TESTING; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; QUALITY CONTROL; RESPIRATORY SYSTEM; RESPIRATORY SYSTEM AGENTS; TECHNOLOGY, PHARMACEUTICAL; WEIGHTS AND MEASURES;

EID: 79954422269     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9590-5     Document Type: Article

References (43)

1. European Directorate for Quality in Medicines (EDQM). European pharmacopeia 6.8, monograph 2.9.18. Preparations for inhalations: Aerodynamic assessment of fine particles. Strasburg, EDQM 2010.
2. US Pharmacopeial Convention. United States Pharmacopeia 33/National Formulary 28, Chapter <601> Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers. Rockville, MD, 2010.
3. D Christopher P Curry W Doub K Furnkranz M Lavery K Lin S Lyapustina J Mitchell B Rogers H Strickland T Tougas Y Tsong B Wyka 2003 Considerations for the development and practice of cascade impaction testing including a mass balance failure investigation tree J. Aerosol Med. 16 3 235 247 10.1089/089426803769017604 14572321 10.1089/089426803769017604 (Pubitemid 37169634)
4. TP Tougas D Christopher JP Mitchell H Strickland B Wyka M Van Oort S Lyapustina 2009 Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs) AAPS PharmSciTech 10 4 1276 1285 10.1208/s12249-009-9312-4 19882251 10.1208/s12249-009-9312-4 1:CAS:528:DC%2BC3cXovVGqtrk%3D
5. Mitchell JP, Morton RW, Nagel MW. The influence of body geometry on spacer performance: a case study. In: Dalby RN, Byron PR, Farr SJ, Peart J, editors. Respiratory drug delivery-VII. Raleigh, North Carolina, USA: Serentec Press; 2000. p. 539-41.
6. Schultz A, Le Soeuf T, Looi K, Zhang G, Le Soeuf P, Devadason SG. Validation of methodology for recording breathing and simulating drug delivery through spacers and valved holding chambers. J Aerosol Med Pulmon Deliv., 2010;23: online in advance of publication.
7. Tougas T, Christopher D, Lyapustina S, Mitchell JP, Patel R. Capabilities of aerodynamic particle size distribution (APSD) measurements based on analysis of a blinded database. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Respiratory drug delivery 2008. Illinois, USA: Davis Healthcare International Publishing LLC, River Grove; 2008. p. 109-23.
8. International Organization for Standardization, Geneva, Switzerland. Aerosol drug delivery device design verification - Requirements and test methods. ISO 20072:2009.
9. Tougas T, Christopher JD, Mitchell JP, Lyapustina S. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Efficient data analysis and abbreviated impactor measurement concepts, respiratory drug delivery 2010. Illinois, USA: Davis Healthcare International Publishing LLC, River Grove; 2010. p. 599-603.
10. JP Mitchell MW Nagel M Copley 2009 The abbreviated impactor measurement concept: a potentially faster and more precise way to assess quality of inhaled drug products Inhalation 3 3 26 30
11. JP Mitchell MW Nagel V Avvakoumova H MacKay R Ali 2009 The abbreviated impactor measurement (AIM) concept: part 1-Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation AAPS PharmSciTech 10 1 243 251 10.1208/s12249-009-9202-9 19280348 10.1208/s12249-009-9202-9 1:CAS:528:DC%2BC3cXotV2muro%3D
12. G Rudolph R Kobrich W Stahlhofen 1990 Modeling and algebraic formulation of regional aerosol deposition in man J. Aerosol Sci. 21 S1 306 406
13. OS Usmani MF Biddiscombe JA Nightingale SR Underwood PJ Barnes 2003 Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols J. Appl. Physiol. 95 2106 2112 12897033 (Pubitemid 37310397)
14. OS Usmani MF Biddiscombe PJ Barnes 2005 Regional lung deposition and bronchodilator response as a function of beta-2 agonist particle size Am. J. Respir. Crit. Care Med. 172 1497 1504 16192448 10.1164/rccm.200410-1414OC (Pubitemid 43076536)
15. European Medicines Agency (EMEA). Guideline on the pharmaceutical quality of inhalation and nasal products. EMEA/CHMP/QWP/49313/2005 Corr. 2006.
16. SP Newman H-K Chan 2008 In vitro/in vivo comparisons in pulmonary drug delivery J Aerosol Med. Pulmon. Deliv. 21 1 1 8 10.1089/jamp.2007.0657
17. Olsson B, Berg E, Svensson M. Comparing aerosol size distributions that penetrate mouth-throat models under realistic inhalation conditions. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Respiratory drug delivery 2010. Illinois, USA: Davis Healthcare International Publishing LLC, River Grove; 2010. p. 225-34.
18. Byron P, Delvadia RR, Worth Longest P, Hindle M. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Respiratory drug delivery 2010. Illinois, USA: Davis Healthcare International Publishing LLC, River Grove; 2010. p. 215-24.
19. B Grgic WH Finlay AF Heenan 2004 Regional aerosol deposition and flow measurements in an idealized mouth and throat J. Aerosol Sci. 35 1 21 32 10.1016/S0021-8502(03)00387-2 1:CAS:528:DC%2BD3sXpt1ensbk%3D (Pubitemid 37476252)
20. JP Mitchell MW Nagel CC Doyle RS Ali VI Avvakoumova JD Christopher J Quiroz H Strickland T Tougas S Lyapustina 2010 Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated Andersen cascade impactors (ACIs): part 1 AAPS PharmSciTech 11 2 843 851 10.1208/s12249-010-9452-6 20480271 10.1208/s12249-010-9452-6 1:CAS:528:DC%2BC3cXptVeqtL0%3D
21. JP Mitchell MW Nagel V Avvakoumova H MacKay R Ali 2009 The abbreviated impactor measurement (AIM) concept: part 2-Influence of evaporation of a volatile component-evaluation with a "droplet producing" pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as co-solvent AAPS PharmSciTech 10 1 252 257 10.1208/s12249-009-9201-x 19291411 10.1208/s12249-009-9201-x 1:CAS:528:DC%2BC3cXotV2murs%3D
22. Stobbs B, McAulay E, Bogard H, Monsallier E. Evaluation of the fast-screening impactor for determining fine particle fraction of dry powder inhalers, drug delivery to the lungs-20. UK: Edinburgh; 2009. p. 158-61.
23. Copley M, Mitchell J, McAulay E, Russell-Graham D. Implementing the AIM concept, Inhalation, 2010;4 (1).
24. Sheng G, Zhang J, Simmons R, Watanabe W. Fast screening impactor (FSI) as a prescreening tool for MDIs and nebulizers. RDD. 2010;637-640.
25. C Dunbar JP Mitchell 2005 Analysis of cascade impactor mass distributions J. Aerosol Med. 18 4 439 451 16379619 10.1089/jam.2005.18.439 1:CAS:528:DC%2BD2MXhtlCntbnL (Pubitemid 43038409)
26. Mitchell JP, Nagel MW, Doyle CC, Ali RS, Avvakoumova VI, Christopher JD, Quiroz J, Strickland H, Tougas T, Lyapustina S. Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated Andersen cascade impactors (ACIs). Part 2-Investigation of Bias in Extra-fine Mass Fraction with AIM-HRT Impactor. Accepted to AAPS PharmSciTech. 2010.
27. PharmEur 2.9.18 - details to come
28. GW Hallworth DG Westmoreland 1987 The twin impinger: a simple device for assessing the delivery of drugs from metered dose pressurized aerosol inhalers J. Pharm. Pharmacol. 39 966 972 2894443 1:CAS:528:DyaL1cXhtFWkug%3D%3D
29. JP Mitchell MW Nagel 2003 Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations J. Aerosol Med. 16 4 341 377 14977427 10.1089/089426803772455622 1:CAS:528: DC%2BD2cXltFagtw%3D%3D (Pubitemid 38120942)
30. Leach C. Enhancing drug delivery through reformulating MDIs with HFA propellants-drug deposition and its effect on preclinical programs. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove: IL. InterpharmPress; 1996. p. 133-44.
31. MB Dolovich JP Mitchell 2004 Canadian standards association (CSA) standard Z264.1-02: a new voluntary standard for spacers and holding chambers used with pressurized metered-dose inhalers (pMDIs) Can. Respir. J. 11 7 489 495 15505702 (Pubitemid 39549460)
32. Mitchell JP, Nagel MW, MacKay H, Avvakoumova VA, Malpass J. Developing a "universal" valved holding chamber (VHC) platform with added patient benefits whilst maintaining consistent in vitro performance. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM, editors. Respiratory drug delivery-Europe. Illinois, USA: Davis Healthcare International Publishing LLC, River Grove; 2009. p. 383-6.
33. SP Newman HK Chan 2008 In vitro/in vivo comparisons in pulmonary drug delivery J. Aerosol Med. Pulm. Drug Deliv. 21 1 77 84 10.1089/jamp. 2007.0643 18518834 10.1089/jamp.2007.0643 1:CAS:528:DC%2BD1cXjvFehs70%3D
34. American Thoracic Society 1995 Standardization of spirometry, 1994 update Am. J. Respir. Crit. Care Med. 152 1107 1136
35. Hinds WC. Properties, behavior, and measurement of airborne particles. 2nd ed. N.Y., USA: Wiley-Interscience; 1999. p. 75-110.
36. Leach C. Enhanced drug delivery through reformulating MDIs with HFA propellants-drug deposition and its effect on preclinical programs. RDD. 1996;133-144.
37. Gonda I. Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract, In: Critical reviews in therapeutic drug carrier systems, 1990;273-313. (Pubitemid 20216394)
38. Vincent JH. The inhalation of aerosols. In: Aerosol science for industrial hygienists, New York, Pergamon, 1995, pp 136-155.
39. DA Lundgren DN Hlaing TA Rich VA Marple 1996 PM10/PM2:5/PM1 data from a trichotomous sampler Aerosol Sci. Technol. 25 353 357 10.1080/02786829608965401 1:CAS:528:DyaK28XlvFOktLY%3D
40. Y Zhang WH Finlay EA Matida 2004 Particle deposition measurements and numerical simulation in a highly idealized mouth-throat J. Aerosol Sci. 35 7 789 803 10.1016/j.jaerosci.2003.12.006 10.1016/j.jaerosci.2003.12.006 1:CAS:528:DC%2BD2cXlsVShtLY%3D (Pubitemid 38953779)
41. PT Daley-Yates DA Parkins MJ Thomas B Gillett KW House HG Ortega 2009 Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 μg and fluticasone propionate 250 μg: Implications for establishing bioequivalence of inhaled products Clin Thera. 31 2 370 385 10.1016/j.clinthera.2009.02.007 10.1016/j.clinthera.2009.02.007 1:CAS:528:DC%2BD1MXkvVCqsrs%3D
42. B Grgic WH Finlay PKP Burnell AF Heenan 2004 In vitro intersubject and intrasubject deposition measurements in realistic mouth-throat geometries J. Aerosol Sci. 35 1025 1040 10.1016/j.jaerosci.2004.03.003 1:CAS:528: DC%2BD2cXmtFCnsL8%3D (Pubitemid 38993745)
43. L Borgström B Olsson L Thorsson 2006 Degree of throat deposition can explain the variability in lung deposition of inhaled drugs J Aer Medicine. 19 4 473 483 10.1089/jam.2006.19.473 (Pubitemid 46067766)